drugset / Trial / NCT00093093

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

NCT00093093

Phase 3 Completed 900 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.

Timeline

Start
2004-06
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg
Subject Taribavirin Small molecule 600 mg
Background Peginterferon alfa-2a Protein / enzyme biologic